These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37708925)

  • 41. Microneedles fabricated from alginate and maltose for transdermal delivery of insulin on diabetic rats.
    Zhang Y; Jiang G; Yu W; Liu D; Xu B
    Mater Sci Eng C Mater Biol Appl; 2018 Apr; 85():18-26. PubMed ID: 29407146
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
    Franek E; Haluzík M; Canecki Varžić S; Sargin M; Macura S; Zacho J; Christiansen JS
    Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Continuous Glucose Monitoring Sensor Glucose Levels and Insulin Pump Infusion Set Wear-Time During Treatment with Fast-Acting Insulin Aspart: A Post Hoc Analysis of Onset 5.
    Gorst-Rasmussen A; Sturis J; Ekelund M
    Diabetes Technol Ther; 2022 Jan; 24(1):10-17. PubMed ID: 34524005
    [No Abstract]   [Full Text] [Related]  

  • 44. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
    Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
    Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Yang Y; Long C; Li T; Chen Q
    Front Endocrinol (Lausanne); 2022; 13():890090. PubMed ID: 35721710
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin.
    Rosenfalck AM; Thorsby P; Kjems L; Birkeland K; Dejgaard A; Hanssen KF; Madsbad S
    Acta Diabetol; 2000 Mar; 37(1):41-6. PubMed ID: 10928235
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Extent and prevalence of post-exercise and nocturnal hypoglycemia following peri-exercise bolus insulin adjustments in individuals with type 1 diabetes.
    McCarthy O; Deere R; Churm R; Dunseath GJ; Jones C; Eckstein ML; Williams DM; Hayes J; Pitt J; Bain SC; Moser O; Bracken RM
    Nutr Metab Cardiovasc Dis; 2021 Jan; 31(1):227-236. PubMed ID: 33012641
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transdermal delivery of insulin with bioceramic composite microneedles fabricated by gelatin and hydroxyapatite.
    Yu W; Jiang G; Liu D; Li L; Tong Z; Yao J; Kong X
    Mater Sci Eng C Mater Biol Appl; 2017 Apr; 73():425-428. PubMed ID: 28183628
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative efficiency and safety of insulin degludec/aspart with insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials.
    Long T; Lin JT; Lin MH; Wu QL; Lai JM; Li SZ; Zhou ZC; Zeng JY; Huang JS; Zeng CP; Lai YM
    Endocr J; 2022 Aug; 69(8):959-969. PubMed ID: 35431280
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacological Properties of Faster-Acting Insulin Aspart.
    Biester T; Kordonouri O; Danne T
    Curr Diab Rep; 2017 Sep; 17(11):101. PubMed ID: 28940145
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Integration of metformin-loaded MIL-100(Fe) into hydrogel microneedles for prolonged regulation of blood glucose levels.
    Feng M; Li Y; Sun Y; Liu T; Yunusov KE; Jiang G
    Biomed Phys Eng Express; 2024 May; 10(4):. PubMed ID: 38670077
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial.
    Cho KY; Nakamura A; Oba-Yamamoto C; Tsuchida K; Yanagiya S; Manda N; Kurihara Y; Aoki S; Atsumi T; Miyoshi H
    Diabetes Metab J; 2020 Aug; 44(4):532-541. PubMed ID: 31769240
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Glucose-Responsive Silk Fibroin Microneedles for Transdermal Delivery of Insulin.
    Tan G; Jiang F; Jia T; Qi Z; Xing T; Kundu SC; Lu S
    Biomimetics (Basel); 2023 Jan; 8(1):. PubMed ID: 36810381
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes.
    Dardano A; Bianchi C; Del Prato S; Miccoli R
    Vasc Health Risk Manag; 2014; 10():465-75. PubMed ID: 25143741
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combined Silk Fibroin Microneedles for Insulin Delivery.
    Zhu M; Liu Y; Jiang F; Cao J; Kundu SC; Lu S
    ACS Biomater Sci Eng; 2020 Jun; 6(6):3422-3429. PubMed ID: 33463180
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus.
    Philis-Tsimikas A; Astamirova K; Gupta Y; Haggag A; Roula D; Bak BA; Fita EG; Nielsen AM; Demir T
    Diabetes Res Clin Pract; 2019 Jan; 147():157-165. PubMed ID: 30448451
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Addition of insulin aspart with basal insulin is associated with improved glycemic control in Indian patients with uncontrolled type 2 diabetes mellitus: the A1chieve observational study.
    Banerjee S; Maji D; Baruah M
    J Assoc Physicians India; 2013 Jan; 61(1 Suppl):24-7. PubMed ID: 24482984
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes in Malaysia: Results from a Prospective, Non-interventional Real-World Study.
    Mohamed M; Lim SC; Mumtaz M; Uppal S; Mukherjee D; Kassim MSM; Sreedharan S; Doraiswamy AM; Chong KM; Tat LY; Nordin SB; Giek JLH; Hussein Z; Kadir KA; Lau BK; Chan SP
    J ASEAN Fed Endocr Soc; 2023; 38(1):37-44. PubMed ID: 37252419
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial.
    Taneda S; Hyllested-Winge J; Gall MA; Kaneko S; Hirao K
    J Diabetes; 2017 Mar; 9(3):243-247. PubMed ID: 27059529
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study.
    Akturk HK; Snell-Bergeon JK; Rewers A; Klaff LJ; Bode BW; Peters AL; Bailey TS; Garg SK
    Diabetes Technol Ther; 2018 Oct; 20(10):639-647. PubMed ID: 30207748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.